Nanoparticle imaging agent could spot hidden tumors in women with advanced cancer
NCT ID NCT06977126
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-stage trial tests a new imaging drug called porphysome nanoparticles in 24 women with advanced gynecological cancers that have spread. The goal is to see if the drug is safe and how it travels through the body to improve PET/CT scans. Participants will receive one dose of the drug and be monitored for side effects and tumor visibility.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGICAL CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Conditions
Explore the condition pages connected to this study.